Olpasiran for Cardiovascular Disease

(OCEAN(a)-CCTA Trial)

This trial tests a new treatment called olpasiran to determine if it can reduce the buildup of non-calcified plaque in the arteries of people with heart disease. The researchers aim to compare the effects of olpasiran, administered as an injection every 12 weeks, with a placebo (a non-active substance). Suitable candidates for this trial have heart disease, high levels of Lp(a) (a specific type of cholesterol), and a history of heart attacks or certain heart procedures. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that olpasiran is generally safe and well-tolerated. Studies have found that side effects are uncommon, and most participants did not experience serious problems while taking the treatment. In earlier studies, researchers tested the drug on individuals with heart issues and successfully lowered lipoprotein(a), a type of cholesterol linked to heart disease.

Olpasiran is unique because it targets lipoprotein(a), a specific type of cholesterol linked to cardiovascular disease, which current treatments usually overlook. Most available therapies, like statins, primarily focus on lowering LDL cholesterol, but they don't effectively address high levels of lipoprotein(a). Researchers are excited about olpasiran because it offers a new mechanism of action by potentially reducing this specific cholesterol component, providing an innovative option for patients at risk of heart disease. Additionally, olpasiran is administered subcutaneously once every 12 weeks, offering a convenient dosing schedule compared to daily oral medications.

Research has shown that olpasiran, which participants in this trial may receive, can significantly lower lipoprotein(a) levels, a type of cholesterol linked to heart disease. In studies, olpasiran reduced lipoprotein(a) by over 95% in people with heart conditions and also decreased other harmful cholesterol types, such as LDL, often called "bad cholesterol." Even after stopping the treatment, patients who took olpasiran experienced a 40% to 50% reduction in lipoprotein(a). These findings suggest that olpasiran could help manage heart conditions by targeting specific cholesterol types.¹⁴⁵⁶⁷